PLK1 has been shown to be a valid target in MYC-driven cells such as lymphoma [38], glioma [39], and medulloblastoma, where onvansertib sensitized tumors to radiotherapy [40], and pediatric malignancies synergizing with vincristine [41]. This evidence concerns the gene MYC and lymphoma.